Castle Biosciences Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
24.2%projected annual EPS growth
Analyst Coverage
9analysts covering
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
TissueCypher Test Volume Growth Quarterly5,800.0%Target: Approach 50% growth for the full year 2026
DecisionDx-Melanoma Test Volume Growth Quarterly1,600.0%Target: Double-digit year-over-year growth
Total Revenue Quarterly83.7MTarget: $345 million to $355 million for full year 2026
Watch Items
- Medicare Local Coverage Determination (LCD) for DecisionDx-SCCTrigger: Reinstatement or non-coverage update from CMSAction: Re-evaluate dermatologic test revenue projections and commercial sales force allocation.
- AdvanceAD-Tx Reimbursement StatusTrigger: Reimbursement update expected by the end of Q3 2026Action: Assess commercial launch timeline and long-term revenue contribution models for 2027/2028.
- Operating Expense (OpEx) Outpacing Revenue GrowthTrigger: Adjusted EBITDA margin deterioration or annual EPS decline exceeding 40%Action: Review commercial infrastructure expansion and R&D spending discipline.
Research as of 19 Jun 2026